Esketamine for Treatment-resistant Depression

featured image
Indications: Depression
Therapeutic Areas: Mental and Behavioural Health
Year: 2017

Those who do not respond to at least two therapies, are regarded as having ‘treatment-resistant depression.’ Currently there are no approved treatments for patients with depression who are at an imminent risk for suicide. Esketamine is currently in development as a spray through the nose (intranasal) for the treatment of treatment-resistant depression in adults. Compared to treatment options that require injections, esketamine is less invasive and is considered easier to use as it is a nasal spray. If licensed, esketamine may be a safe and effective treatment option for this hard to treat population.